Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PET and digestive cancers].

Jean-Noël Talbot1, Françoise Montravers, Fabrice Gutman

  • 1Service de médecine nucléaire, AP-HP, Hôpital Tenon, F-75020 Paris, France. jean-noel.talbot@tnn.aphp.fr

Presse Medicale (Paris, France : 1983)
|October 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis.

Annals of surgical oncology·2026
Same author

Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis.

Annals of surgical oncology·2026
Same author

Focal congenital hyperinsulinism: spontaneous glycemic improvement before surgery.

The Journal of clinical endocrinology and metabolism·2026
Same author

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

JHEP reports : innovation in hepatology·2026
Same author

Functional Estrogen Receptor Assessment: Insights From Discordant 18 F-FES PET/CT and ER Immunohistochemistry.

Clinical nuclear medicine·2026
Same author

Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab.

JHEP reports : innovation in hepatology·2026
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Fluorodeoxyglucose Positron Emission Tomography (FDG PET) is crucial for detecting recurrent colorectal cancer and aiding preoperative staging in various digestive cancers. Research also explores new tracers like fluoromethylcholine-(18F) and fluoroDOPA-(18F) for specific cancers.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Digestive oncology frequently utilizes Fluorodeoxyglucose Positron Emission Tomography (FDG PET) for recurrent colorectal cancer detection.
  • FDG PET is also valuable for preoperative staging across multiple digestive system cancers.

Purpose of the Study:

  • To review the current applications of FDG PET in digestive oncology.
  • To highlight emerging PET tracer developments for specific cancers like hepatocellular carcinoma and gastrointestinal endocrine tumors.

Main Methods:

  • Review of clinical experience and literature on FDG PET in digestive cancers.
  • Discussion of current practices and evaluated tracers for specific tumor types.

Main Results:

Related Experiment Videos

  • FDG PET is the primary method for locating recurrent colorectal cancer.
  • Clinical utility is demonstrated in preoperative staging for colorectal, esophageal, gastric, pancreatic, hepatic, and biliary cancers.
  • Investigational tracers like fluoromethylcholine-(18F) and fluoroDOPA-(18F) show promise for hepatocellular carcinoma and gastrointestinal endocrine tumors.

Conclusions:

  • FDG PET is an established tool in digestive oncology, particularly for colorectal cancer recurrence and staging.
  • Ongoing research into novel PET tracers will expand molecular imaging's role in managing complex digestive malignancies.